Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Net Margin (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Net Margin for 13 consecutive years, with 18.08% as the latest value for Q3 2025.

  • On a quarterly basis, Net Margin rose 9336.0% to 18.08% in Q3 2025 year-over-year; TTM through Sep 2025 was 36.55%, a 11569.0% increase, with the full-year FY2024 number at 87.63%, down 229980.0% from a year prior.
  • Net Margin was 18.08% for Q3 2025 at Theravance Biopharma, down from 209.22% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 7445.92% in Q3 2022 to a low of 558.88% in Q1 2021.
  • A 5-year average of 396.33% and a median of 75.28% in 2024 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: surged 786841bps in 2022, then tumbled -750295bps in 2023.
  • Theravance Biopharma's Net Margin stood at 422.5% in 2021, then soared by 106bps to 26.58% in 2022, then tumbled by -315bps to 57.03% in 2023, then crashed by -45bps to 82.79% in 2024, then soared by 122bps to 18.08% in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Net Margin are 18.08% (Q3 2025), 209.22% (Q2 2025), and 87.98% (Q1 2025).